Celyad
Mont-saint-guibert
About Celyad
Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $157.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:CYAD
- Website: celyad.com
- Phone: +32(0) 10 39 41 00
Industries & Categories
Biotechnology, Medical Device, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/celyad-209770 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.